highly significantp < .001
Treatment with GD2-CAR-T led to a highly significant reduction in tumor growth compared to CD19-CAR-T cells ( p < .001) and the PBS-injected control ( p < .001) ( Figure 4a – c and Supplementary Figure 4a,b).
Treatment with GD2-CAR-T led to a highly significant reduction in tumor growth compared to CD19-CAR-T cells ( p < .001) and the PBS-injected control ( p < .001) ( Figure 4a – c and Supplementary Figure 4a,b).